UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 100

References
Adams, AS (2001). The case for a medicare drug coverage benefit: a critical review of the
empirical evidence. Annual Review of Public Health , 22, 49-61.
Armstrong, EP and PC Langley (1996). Disease management programs. American Journal
of Health System Pharmacy , 53(1), 53-58.
Atun, RA and I Gurol-Urganci (2006). Factors influencing the uptake and diffusion of
pharmaceutical innovations: a systematic review. Imperial College London, Tanaka
Business School Discussion Paper.
Atun, RA and N Menabde (2007). Health systems and systems thinking. In Health Systems
and CommunicableDiseases: Challenges to Transitional Societies ,RJCoker,RAAtun
and M McKee (eds.). European Observatory in Health Systems and Open University
Press, forthcoming.
Atun, RA et al . (2005). Analysis of how the health systems context shapes responses to the
control of human immunodeficiency virus: case-studies from the Russian Federation.
Bulletin of the World Health Organization , 83(10), 730-738.
Atun, RA et al . (2007a). Diffusion of complex health innovations—implementation of
primary care reforms in Bosnia and Herzegovina: qualitative study. Health Policy and
Planning , 22(1), 28-39.
Atun, RA et al . (2007b). Innovation, patents and economic growth. International Journal
of Innovation Management , 11(2), 279-297.
Bae, JP (1997). Drug patent expirations and the speed of generic entry. Health Services
Research , 32(1), 87-101.
Bateman, DN et al . (1996). A prescribing incentive scheme for non-fundholding gen-
eral practices: an observational study. British Medical Journal , 313(7056), 535-
538.
Berndt, E (2005). The U.S. pharmaceutical industry why major growth in times of cost
containment. Health Affairs , 20(2), 100-114.
Blustein, J (2000). Drug coverage and drug purchases by medicare beneficiaries with hyper-
tension. Health Affairs , 19(2), 219-230.
Bradlow, J and A Coulter (1993). Effect of fundholding and indicative prescribing schemes
on general practitioners' prescribing costs. British Medical Journal , 307(6913), 1186-
1189.
Brouwers, CA, MB Silverstein and T Wolff (2004). Adverse consequences of OECD gov-
ernment interventions in pharmaceutical markets on the U.S. economy and consumer.
BCG White Paper .
Burstall, ML (1997). The management of the cost and utilisation of pharmaceuticals in the
United Kingdom. Health Policy , 41 (Suppl), S27-S43.
Calfee, JE (2000). The increasing necessity for market-based pharmaceutical prices. Phar-
macoeconomics , 18(Suppl 1), 47-57.
Calfee, JE (2001). Pharmaceutical price controls and patient welfare. Annals of Internal
Medicine , 134(11), 1060-1064.